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Kawasaki Disease is a small-to-medium-vessel vasculi-
tis that preferentially affects children. Kawasaki Dis-
ease can occur in adults, but the presentation may
differ from that observed in children. Typical findings in
both adults and children include fever, conjunctivitis,
pharyngitis, and skin erythema progressing to a des-
quamating rash on the palms and soles. Adults more
frequently present with cervical adenopathy (93% of
adults vs. 15% of children), hepatitis (65% vs. 10%),
and arthralgia (61% vs. 24–38%). In contrast, adults are
less frequently affected by meningitis (10% vs. 34%),
thrombocytosis (55% vs. 100%), and coronary artery
aneurysms (5% vs. 18–25%). We report a case of acute
Kawasaki Disease in a 24-year-old man who presented
with rash, fever, and arthritis. He was successfully
treated with high-dose aspirin and intravenous immu-
noglobulin (IVIG). Our case highlights the importance of
considering Kawasaki Disease in adults presenting with
symptoms commonly encountered in a general medical
practice.
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INTRODUCTION
Kawasaki Disease is a small-to-medium-vessel vasculitis that
preferentially affects infants and young children. The first cases
were identified among Japanese children in the 1960s.
1 Acute
Kawasaki Disease is rare in adults, and therefore the diagnosis
can easily be missed in a patient presenting to a primary care
clinic. We describe an adult with Kawasaki Disease and review
the literature regarding this rare adult illness.
CASE DESCRIPTION
A 24-year-old White man presented to our hospital with a
3-week illness that began in early February with fever,
headache, nausea, sore throat, and cough, followed 5 days
later by arthralgia. Two weeks later the patient noted an
erythematous, diffuse skin rash beginning on his torso and
spreading to his extremities. At a local hospital, he was
diagnosed with scarlet fever and placed on penicillin, although
a throat culture was negative for Streptococcal species. His
skin desquamated from his fingernails, progressing centrally.
He was placed on cephalexin and referred to our institution.
The patient was previously healthy and reported no drug
allergies. He worked as a dairy farmer in Wisconsin. He
recently married and traveled to Las Vegas on his honeymoon.
He denied intravenous drug use, new sexual partners, or
tattoos. Animal exposure included contact with domestic cats,
cattle, and deer. The patient did not use tobacco products but
consumed alcohol socially. His father was recently ill with an
upper respiratory infection; no other ill contacts were identi-
fied. The family history was otherwise noncontributory and the
patient identified no Asian antecedents or family members
with rheumatic disease. Review of systems was positive for a
self-reported 20-pound weight loss over the course of the
illness, although the patient’s clothes fit normally. He denied
cardiac, pulmonary, or gastrointestinal symptoms.
On physical examination, the patient’s temperature was
38.3°C, his pulse was 96 beats per minute and regular, and
his blood pressure was 119/65 mmHg. We observed a
desquamating rash involving his fingers, palms, and soles.
Radial pulses were easily palpable and symmetric. Head and
neck examination revealed injected conjunctivae with spar-
ing of the limbi, dry mucus membranes with an erythema-
tous pharynx, fissured tongue, and 2 labial ulcers. An 8-cm
firm, nontender, matted mass was visible over the right
anterior neck with scattered adjacent palpable anterior
cervical lymph nodes. A I/VI systolic heart murmur was
audible at the right upper sternal border. Musculoskeletal
examination revealed a small right knee effusion without
warmth or erythema and pain with active motion of the wrists,
hips, knees, and ankles. Examination of the lungs, abdomen,
and neurologic systems were normal.
Initial laboratory tests were notable for an anemia (hemato-
crit, 29 mL/dL),a mildly elevated platelet count (363,000 L/uL),
and an elevated erythrocyte sedimentation rate and C-reactive
protein (89 mm/hr and 30 mg/dL, respectively). Hepatitis was
evident with an elevated AST (276U/L), ALT (375U/L), alkaline
phosphatase (149U/L), and GGT (112U/L). The ASO titer was
normal and the sodium was low at 131 mmol/L. A positive anti-
nuclearantibody(ANA)wasnoted(1:160titer,nucleolarpattern).
Diagnostic considerations at the time of admission were
diverse. Infectious illnesses were suggested based on recent
fever, headache, sore throat, cough, heart murmur, and
monoarthritis. We suspected streptococcal or staphylococcal
bacteremia leading to bacterial endocarditis and/or septic
arthritis. Vector-born illnesses were also entertained including
Brucellosis and Lyme disease. Marked cervical adenopathy
raised concern for cervical abscess, acute HIV, or Epstein-Barr
virus infection.
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681Autoimmune diseases were also entertained. In particular,
arthritis, throat pain, elevated platelets and liver enzymes
suggested Adult Still’s disease, although the normal white
count and desquamating rash were atypical. Systemic vasculi-
tis might explain the patient’s constitutional symptoms, ocular,
joint, and liver inflammation, although he did not have nephri-
tis or palpable purpura. Systemic lupus erythematosus was
entertained on the basis of arthritis, anemia, and positive ANA,
although male gender made this diagnosis less likely. Finally,
Kawasaki Disease was a possibility, although the rarity of this
disease in adults demanded exclusion of other conditions.
We considered other diseases as well. Malignancy was
considered because of significant weight loss, anemia, and
striking cervical adenopathy, although physical examination
revealed a well-nourished male without muscle wasting,
suggesting that self-reported weight loss was inaccurate. A
hypersensitivity drug reaction could cause arthritis and rash,
but would not explain presenting symptoms or be expected to
cause hepatitis.
Subsequent diagnostic tests were directed at excluding
infections and confirming a working diagnosis of Kawasaki
Disease. Synovial fluid from the right knee contained 6,600
nucleated cells with a predominance of polymorphonucleo-
cytes (78%); bacterial cultures were negative. Six blood
cultures were also negative. A chest x-ray and electrocardio-
gram were normal as was a transthoracic echocardiogram. A
computerized tomographic scan of the neck showed right
cervical lymphadenopathy and multiple hypoattenuating
lymph nodes. A brucellosis titer was negative. A Lyme test
was not requested because of the winter-time presentation.
Kawasaki Disease was diagnosed based on the absence of
infection, failure to improve with antibiotic therapy, and the
presence of all diagnostic criteria for childhood Kawasaki
Disease (Table 1). More specifically, the patient had fever,
desquamating rash of the palms and soles, bilateral nonsup-
perative conjunctivitis, significant cervical lymphadenopathy,
oral changes including pharyngitis, a fissured tongue and labial
ulcers, and extremity edema (Table 1). Additionally, hepatitis
and joint complaints were explained by this diagnosis, as these
features are common in adults with Kawasaki Disease (Table 2).
Chest computerized tomography with coronary artery pro-
tocol subsequently revealed no aneurysms or stenotic lesions.
The patient was subsequently treated with 1,000 mg of aspirin
daily and IVIG at 400 mg/kg/day for 4 days, with clinical
improvement illustrated by rapid resolution of arthritis, oral
findings, conjunctivitis, and rash. IVIG was administered over
4 days to minimize exacerbation of preexisting hyponatremia
and to lessen the risk of osmotic nephropathy and hypervis-
cosity. He was discharged on 325 mg (4.6 mg/kg) of aspirin
daily. Repeat chest computerized tomographic imaging with
coronary artery protocol completed 2 months later confirmed
the absence of coronary artery aneurysms.
DISCUSSION
Kawasaki Disease is a childhood vasculitis involving small and
medium-sized arteries.
1,2 Over 90% of cases occur in young
children and infants. Japan reports an annual incidence of
112 cases per 100,000 children under age 5 years; new cases
preferentially affect male infants.
3 In contrast, American cases
appear more commonly in toddlers and number about 10 per
100,000 children.
4 Less than 60 patients with acute adult
Kawasaki Disease have been reported, most of whom present
between the ages of 18 and 30 years and represent patients
from North America (n=23), South America (n=2), Asia (n=5),
Africa (n=2), and Europe (n=25).
2 To date, there are no
reported deaths from acute adult Kawasaki Disease.
The pathogenesis of Kawasaki Disease is unknown, al-
though seasonal outbreaks suggest a possible infectious
source, with cases presenting more commonly in winter and
summer.
5 Leung and colleagues suggested a bacterial super-
antigen as the trigger for Kawasaki Disease.
12 Such a reaction
might occur in subsets of patients with susceptibility to a
specific microbial infection. An outbreak of Kawasaki Disease
occurred after exposure to carpet cleaner, supporting argu-
ments for an environmental trigger.
13
The diagnostic criteria for Kawasaki Disease were developed
for children and have not been validated in adults. Kawasaki
Disease is marked by 5 or more days of fever or coronary artery
aneurysms, plus at least 4 other diagnostic criteria (Table 1). In
a recent analysis of 57 adult cases, Seve summarized the
difference in presentation between children and adults with
Kawasaki Disease (Table 2)
2. Adults more frequently present
with cervical adenopathy (93% of adults vs. 15% of children),
hepatitis (65% vs. 10%), and arthralgia (61% vs. 24–38%). In
contrast, adults are less frequently affected by meningitis (10%
vs. 34%), thrombocytosis (55% vs. 100%), and coronary artery
aneurysms (5% vs. 18–25%).
Kawasaki Disease can be divided into 3 phases: acute,
subacute, and chronic. The acute phase lasts approximately
3 weeks and is marked by fever, carditis, mucocutaneous
changes, and a polymorphous rash.
6 Coronary artery aneu-
rysms typically develop in the acute phase.
2 Symmetric,
polyarticular arthralgias may occur and favor larger joints.
2
Table 1. Diagnostic Criteria for Kawasaki Disease
1
Fever >5 Days or Coronary Artery Aneurysms and at Least 4 Additional
Criteria:
1. Polymorphous rash
2. Conjunctivitis
3. Cervical lymphadenopathy with lymph nodes >1.5 cm in size
4. Oral changes including injected pharynx or lips, cracked or fissured
lips, strawberry tongue
5. Extremity changes starting with edema or erythema then progressing
to desquamation of the feet or hands starting periungually
Table 2. A Comparison of Clinical Findings in Adults and Children
with Kawasaki Disease
2
Clinical Finding Adults (%) Children (%)
Desquamation 96 94
Conjunctivitis 93 95
Cervical Adenopathy 93 15
Injected pharynx 80 90
Strawberry tongue 80 77
Erythema of the palms and soles 80 88
Liver function test abnormalities 65 10
Arthralgia 61 24–38
Thrombocytosis 55 100
Meningitis 10 34
Coronary aneurysms 5 20
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and perineal desquamation, arthralgia and myocardial disease
may develop.
6 In the convalescent or chronic phase lasting
weeks to months, the sedimentation rate normalizes, but
cardiac disease may persist.
6
In adult patients with acute Kawasaki Disease, diagnostic
considerations include viral and vector-born infections, scarlet
fever with lymphadenitis, toxic shock syndrome, adult onset
Still’s disease, systemic lupus erythematosus, vasculitis, and
hypersensitivity drug reaction. Laryngitis, cough, and rhinor-
rhea suggest a viral infection and are uncommon in Kawasaki
Disease. By contrast, patients with Kawasaki Disease often
develop skin changes atypical for viral infections, including a
desquamating rash of the palms and soles, painful erythema,
and peripheral edema.
7 Desquamation may occur in toxic
shock syndrome and scarlet fever, but is more extensive. The
lips are red and cracked in both Kawasaki Disease and toxic
shock syndrome. Conjunctivitis is nonspecific and may occur
during viral or bacterial infections, but anterior uveitis, if
present, would support Kawasaki Disease.
Laboratory abnormalities commonly found in Kawasaki
Disease include an elevated erythrocyte sedimentation rate
and/or C-reactive protein, elevated alanine aminotransferase,
thrombocytosis (platelets>450,000 K/μL), leukocytosis (white
cells>15,000 K/uL), anemia, sterile pyuria, and a positive
antineutrophilic cytoplasmic antibody. Mild hyponatremia, as
seen in this case, may also occur.
2
A positive ANA is uncommon in Kawasaki Disease. Among
84 Italian children with Kawasaki Disease, none had a positive
ANA.
8 In another series, less than one third of fourteen
children with Kawasaki Disease had a positive ANA.
9 A single
adult woman with Kawasaki Disease had an ANA of 1:160
(pattern not reported).
10 In summary, the positive ANA in our
patient is unusual; there was no evidence of an underlying
connective tissue disease in the patient or his relatives. If an
infectious trigger precipitated the illness, this might explain
the positive ANA, as viral infections are known to induce
autoantibodies.
11
COMPLICATIONS
In the acute stage of the illness lasting approximately 10 days,
perivascular inflammation leads to panvasculitis. The vascular
inflammation may progress to complete vascular obstruction,
thrombosis, aneurysm, or fibrosis. It is believed that when
IVIG is initiated within 10 days of illness, extension of the
perivasculitis to panvasculitis is interrupted.
14
Coronary artery aneurysms form in 18–25% of pediatric
cases, but only 5% of adult cases.
2,15 Aneurysms most
commonly form at the arterial bifurcations of proximal seg-
ments, and are associated with premature atherosclerosis and
subsequent myocardial infarction.
15 Interestingly, 50–75% of
aneurysms resolve without intervention, although microscopic
fibrosis may alter vessel mechanics over the long term.
14
Electrocardiograms, stress tests, and echocardiograms are
used to screen and follow patients with coronary artery
involvement. Cardiac catheterization is recommended if the
patient develops ischemic symptoms or if stress testing reveals
reversible ischemia.
1 Further study is needed to establish
evidence supporting a preferred screening modality for adults.
TREATMENT
Information regarding the utility of IVIG and aspirin therapy is
based on research performed in children, as cases of acute
adult Kawasaki Disease are extremely rare. In children, IVIG
reduces the incidence of coronary artery aneurysms if given
within the first 10 days of disease onset.
16 IVIG may help
shorten disease duration even if started after the acute phase.
ThestandardofcareforchildrenwithacuteKawasakiDiseaseis
asingle2-gm/kginfusionofIVIGalongwith80–100mg/kg/day
of aspirin in 4 divided doses.
1,16,17 Once the fever resolves,
the aspirin may be decreased to 3–5 mg/kg/day.
1,17 In patients
with coronary artery aneurysms, aspirin should be continued
until 2 years after the aneurysms resolve. If aneurysms
do not resolve, then aspirin therapy is recommended indefi-
nitely to prevent coronary artery thrombosis.
1 Unlike IVIG,
aspirin does not decrease the formation rate of coronary
aneurysms.
17
Initial trials of IVIG therapy used a low dose administered
over 4 days. In a pivotal trial, aspirin monotherapy was
compared to 400 mg/kg/day of IVIG plus aspirin in 85
children with Kawasaki Disease.
18 Children receiving IVIG
enjoyed a significant reduction in the incidence of coronary
artery aneurysms (15% vs. 42%, p<.01). Similarly, another trial
randomized 75 children to aspirin and IVIG (400 mg/kg/day
for 4 days) and 78 children to aspirin monotherapy.
16 Two
weeks into the trial, 23% of the aspirin monotherapy group and
8% of the IVIG group had coronary artery aneurysms. At
7 weeks, 18% of the aspirin monotherapy group and 4% of the
IVIG group had coronary artery aneurysms, suggesting a
significant decrease in incidence of coronary artery aneurysms
with IVIG therapy.
16
A more recent trial suggested that a single infusion of IVIG
(2 g/kg) may accelerate resolution of inflammation compared
to the 4-day regimen.
18 Patients receiving 400 mg/kg/day for
4 days were almost twice as likely to have coronary artery
aneurysms than those receiving a single 2-gm/kg dose (14 of
252 patients vs. 6 of 254 patients, p=.067).
18 As a result, the
higher single dose has become the current standard of care
for children with acute Kawasaki Disease.
1,19,20 Although
case reports describe benefit when adults with Kawasaki
Disease receive IVIG, there are no controlled studies regard-
ing the optimal dose, timing, or clinical benefit of IVIG
therapy in adults.
2,14,15,21,22 Potential risks of IVIG therapy
include infusion reactions, volume overload, and osmotic
nephropathy.
Surprisingly, corticosteroid therapy is not recommended for
initial management of Kawasaki Disease, although a recent
metaanalysis reports a reduction in the rate of coronary artery
aneurysms with its use.
24,25 In 92 patients with Kawasaki
Disease, aneurysms developed in 64.7% of the patients treated
with steroids, 20% of those treated with antibiotics, and 11% of
those treated with aspirin
23, raising concern that corticoste-
roids enhance the formation of coronary artery aneurysms. In
a prospective randomized trial comparing aspirin and IVIG
with or without corticosteroid therapy, patients receiving
steroids enjoyed more rapid resolution of fever and shorter
hospitalization, but no significant decrease in the rate of
coronary aneurysms.
24 A recent metaanalysis of 862 children
reported fewer coronary artery aneurysms in patients treated
with corticosteroids [OR 0.546, 95% CI: 0.371–0.803].
25
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In summary, we present an adult male with acute Kawasaki
DiseasewhoimprovedafteraspirinandIVIGtherapy.Clinicians
should consider Kawasaki Disease in a patient presenting with
unusual features such as oral, ocular, cutaneous, or joint
inflammation. Delays in diagnosis may increase the risk for
complications, but fortunately coronary artery aneurysms are
uncommon in adults with Kawasaki Disease.
Because acute Kawasaki Disease is rare in adults, it is
important to publish data on patient presentations and
outcome, which may permit development of diagnostic criteria
and treatment guidelines for adults with Kawasaki Disease.
Additional data on adult patients is needed to establish an
evidence-based standard of care for adults, although such a
trial must involve multiple centers to recruit sufficient
patients. We suggest a worldwide registry for adults with
Kawasaki Disease, to address questions on how to test and
treat adults with the condition.
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